Literature DB >> 19965677

Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.

Rogier M Reijmers1, Richard W J Groen, Henk Rozemuller, Annemieke Kuil, Anneke de Haan-Kramer, Tamás Csikós, Anton C M Martens, Marcel Spaargaren, Steven T Pals.   

Abstract

Expression of the heparan sulfate proteoglycan syndecan-1 is a hallmark of both normal and multiple myeloma (MM) plasma cells. Syndecan-1 could affect plasma cell fate by strengthening integrin-mediated adhesion via its core protein and/or by accommodating and presenting soluble factors via its HS side chains. Here, we show that inducible RNAi-mediated knockdown of syndecan-1 in human MM cells leads to reduced growth rates and a strong increase of apoptosis. Importantly, knockdown of EXT1, a copolymerase critical for HS chain biosynthesis, had similar effects. Using an innovative myeloma xenotransplantation model in Rag-2(-/-)gamma(c)(-/-) mice, we demonstrate that induction of EXT1 knockdown in vivo dramatically suppresses the growth of bone marrow localized myeloma. Our findings provide direct evidence that the HS chains of syndecan-1 are crucial for the growth and survival of MM cells within the bone marrow environment, and indicate the HS biosynthesis machinery as a potential treatment target in MM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965677     DOI: 10.1182/blood-2009-02-204396

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Extracellular matrix: The driving force of mammalian diseases.

Authors:  Renato V Iozzo; Maria A Gubbiotti
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

2.  EXTra hit for mouse osteochondroma.

Authors:  Judith V M G Bovée
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-02       Impact factor: 11.205

3.  N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.

Authors:  Richard W J Groen; Martin F M de Rooij; Kinga A Kocemba; Rogier M Reijmers; Anneke de Haan-Kramer; Marije B Overdijk; Linda Aalders; Henk Rozemuller; Anton C M Martens; P Leif Bergsagel; Marie José Kersten; Steven T Pals; Marcel Spaargaren
Journal:  Haematologica       Date:  2011-08-09       Impact factor: 9.941

4.  SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.

Authors:  Joseph P Ritchie; Vishnu C Ramani; Yongsheng Ren; Annamaria Naggi; Giangiacomo Torri; Benito Casu; Sergio Penco; Claudio Pisano; Paolo Carminati; Monica Tortoreto; Franco Zunino; Israel Vlodavsky; Ralph D Sanderson; Yang Yang
Journal:  Clin Cancer Res       Date:  2011-01-21       Impact factor: 12.531

5.  HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC).

Authors:  Wenhui Wang; Yan Chen; Liang Wu; Yi Zhang; Seungyeul Yoo; Quan Chen; Shiping Liu; Yong Hou; Xiao-Ping Chen; Qian Chen; Jun Zhu
Journal:  BMC Med Genomics       Date:  2022-06-16       Impact factor: 3.622

6.  Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.

Authors:  S Lamorte; S Ferrero; S Aschero; L Monitillo; B Bussolati; P Omedè; M Ladetto; G Camussi
Journal:  Leukemia       Date:  2011-10-25       Impact factor: 11.528

7.  D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo.

Authors:  E V Grigorieva; T Y Prudnikova; N V Domanitskaya; L A Mostovich; T V Pavlova; V I Kashuba; E R Zabarovsky
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

8.  Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4.

Authors:  Leonardo Mirandola; Yuefei Yu; Marjorie R Jenkins; Raffaella Chiaramonte; Everardo Cobos; Constance M John; Maurizio Chiriva-Internati
Journal:  BMC Cancer       Date:  2011-09-16       Impact factor: 4.430

9.  The glycome of normal and malignant plasma cells.

Authors:  Thomas M Moehler; Anja Seckinger; Dirk Hose; Mindaugas Andrulis; Jèrôme Moreaux; Thomas Hielscher; Martina Willhauck-Fleckenstein; Anette Merling; Uta Bertsch; Anna Jauch; Hartmut Goldschmidt; Bernard Klein; Reinhard Schwartz-Albiez
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

10.  Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.

Authors:  Sarala Manandhar; Chang-Gu Kim; Sun-Hee Lee; Soo Hyun Kang; Nikita Basnet; You Mie Lee
Journal:  Oncotarget       Date:  2017-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.